๐ŸŽ Black Friday: up to 50% off of annual plans
TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX ยท Real-Time Price ยท USD
63.34
-1.54 (-2.37%)
At close: Nov 20, 2026, 4:00 PM EST
63.65
+0.31 (0.49%)
After-hours: Nov 20, 2026, 7:56 PM EST

TG Therapeutics Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • Delivered $616M global revenue in 2025, driven by 92% year-over-year BRIUMVI growth and strong Q4. Reaffirmed 2026 guidance of $825โ€“$850M U.S. net revenue, with continued share gains, robust pipeline progress, and expanded commercial initiatives.

  • Briumvi is targeting $585 million in revenue this year, with significant growth expected next year. Market share gains are tied to increasing patient awareness, and targeted sales force expansion is underway. Sub-Q and CAR-T programs are progressing, with key data expected in 2024 and 2026.

  • Briumvi is gaining first-line IV status due to strong data, convenience, and robust patient support. SUB-Q formulation is expected to nearly double the addressable market, with pivotal trial data anticipated by late 2025 or early 2027. Q4 growth is expected to outpace Q3, and direct-to-consumer efforts will expand in 2026.

  • Q3 saw record BRIUMVI sales, 93% revenue growth year-over-year, and raised 2025 guidance to $585M. Profitability continued for a sixth quarter, with strong patient retention, expanding field force, and pipeline progress supporting long-term growth.

  • The company is expanding its market share in the IV MS therapy segment, with strong real-world efficacy and tolerability data. Key pipeline developments include a subcutaneous formulation and a new dosing regimen, with pivotal data expected in 2026โ€“2028. Early-stage programs and ex-US partnerships are progressing, but US sales remain the primary revenue driver.

  • A new $100 million share buyback was announced, and BRIUMVI continues to outperform expectations, with a shift toward direct-to-patient marketing and strong market share growth. Subcutaneous BRIUMVI could nearly double the market opportunity, and business development remains a strategic focus.

  • Q2 2025 saw 91% year-over-year revenue growth, driven by BRIUMVI's expanding market share and strong patient persistence. Full-year revenue guidance was raised to $570โ€“$575 million, with continued investment in SubQ and IV enhancements and a robust cash position of $279 million.

  • BRIUMVI continues to grow in market share and prescriber base, with steady revenue guidance and ongoing product enhancements such as a consolidated dose and subcutaneous formulation. Commercial and marketing efforts are expanding incrementally, while financial strategy focuses on reinvestment and pipeline development.

  • CD20 therapies are expanding in the MS market, with subQ options gaining share and IV remaining dominant. BRIUMVI aims for top market position through innovation, expanded marketing, and new dosing regimens, with pivotal trial data and potential label updates expected by 2027-2028.

  • Q1 2025 saw BRIUMVI U.S. sales reach $119.7 million, up 137% year-over-year, with strong new and repeat patient growth. Full-year revenue guidance was raised to $560 million, and pivotal trials for new dosing regimens and sub-Q formulation are on track.

  • Briumvi continues to gain market share in the competitive MS space, driven by its efficacy, safety, and efficient commercial strategy. Plans include expanding into the subcutaneous market, launching pivotal trials, and targeting $540 million in 2025 global revenue.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021